BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $39,925.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 1,597 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,925.00. Following the transaction, the executive vice president now directly owns 260,601 shares of the company’s stock, valued at approximately $6,515,025. The trade was a 0.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $25.00 on Friday. The stock has a market cap of $1.18 billion, a P/E ratio of -23.58 and a beta of 2.04. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock’s 50-day moving average is $26.62 and its 200-day moving average is $25.50. BioLife Solutions, Inc. has a 1-year low of $14.84 and a 1-year high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same period in the prior year, the business posted ($0.21) earnings per share. Equities research analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Institutional Trading of BioLife Solutions

Several institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in BioLife Solutions by 13.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock valued at $1,835,000 after acquiring an additional 8,258 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in BioLife Solutions in the fourth quarter valued at approximately $31,000. Point72 Asset Management L.P. bought a new stake in BioLife Solutions in the fourth quarter valued at approximately $11,113,000. ProShare Advisors LLC bought a new stake in BioLife Solutions in the fourth quarter valued at approximately $282,000. Finally, Millennium Management LLC boosted its holdings in BioLife Solutions by 49.1% in the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after acquiring an additional 377,111 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on BLFS. KeyCorp boosted their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Northland Securities boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Benchmark reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, HC Wainwright boosted their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, BioLife Solutions has an average rating of “Moderate Buy” and an average price target of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.